Insight into the Stability, Reactivity, Structural and Spectral Properties of the Anti, Syn-endo and Syn-exo Isomers of Bis(N-ethoxy-N-ethyl-dithiocarbamato)Nitrido Technetium-99m [99mTc-N(NOEt)2] Radiopharmaceutical

Nabati, Mehdi

doi:10.22034/chemm.2018.62758

|
|
|
How to cite
RIS EndNote BibTeX APA MLA Harvard Vancouver
|
Share

	Insight into the Stability, Reactivity, Structural and Spectral Properties of the Anti, Syn-endo and Syn-exo Isomers of Bis(N-ethoxy-N-ethyl-dithiocarbamato)Nitrido Technetium-99m [99mTc-N(NOEt)2] Radiopharmaceutical
Article 5, Volume 2, Issue 3. pp. 181-269, Summer 2018, Page 223-238 PDF (1.61 MB)
Document Type: Original Article
DOI: 10.22034/chemm.2018.62758
Author
Mehdi Nabati
Synthesis and Molecular Simulation Laboratory, Chemistry Department, Pars Isotope Company, P.O. Box: 1437663181, Tehran, Iran
Receive Date: 17 March 2018, Revise Date: 27 April 2018, Accept Date: 21 May 2018
Abstract
(Ethoxy(ethyl)amino)methanedithiol is used in nuclear medicines as a ligand for the preparation of diagnostic radiopharmaceuticals. Among the available radionuclide tracers, technetium-99m (99mTc) is a good choice for myocardial perfusion imaging. Among the various cardiac perfusion imaging agents, bis(N-ethoxy-N-ethyl-dithiocarbamato)nitride technetium-99m radiopharmaceutical has a very high uptake. During the present study, the reactivity, stability, structural and spectral properties of anti, syn-endo and syn-exo isomers of bis(N-ethoxy-N-ethyl-dithiocarbamato)nitride technetium-99m radiopharmaceutical were discussed by density functional theory (DFT) computational method. It can be deduced from the theoretically applied computations that the anti- molecular structure is generally more stable than the syn-endo- and syn-exo- ones.
Graphical Abstract

Keywords
Coronary Artery Disease; Density functional theory; Nuclear medicine; Radiopharmaceutical; 99mTc-N(NOEt)2
Main Subjects
Organic Chemistry


References
[1]. Nabati M., Mahkam M. Iran Chem. Commun., 2014, 2:129 [2]. Fagret D., Ghezzi C., Vanzetto G. J. Nucl. Med., 2001, 42:1395 [3]. Hatada K., Riou L.M., Ruiz M., Yamamichi Y., Duatti A., Lima R.L., Goode A.R., Watson D.D., Beller G.A., Glover D.K. J. Nucl. Med., 2004, 45:2095 [4]. Nabati M. Iran. J. Org. Chem., 2017, 9:2045 [5]. Takahana K., Beller G.A., Ruiz M., Petruzella F.D., Watson D.D., Glover D.K. J. Nucl. Med., 2001, 42:1388 [6]. Nabati M., Salehi H. Iran. J. Org. Chem., 2017, 9:2013 [7]. Nabati M., Mofrad M.H., Kermanian M., Sarshar S. Iran. J. Org. Chem., 2017, 9:1981 [8]. Nabati M., Kermanian M., Maghsoudloo-Mahalli A., Sarshar S. Iran. J. Org. Chem., 2017, 9:2067 [9]. Hernandez-Valdes D., Blanco-Gonzalez A., Garcia-Fleitas A., Rodriguez-Riera Z., Meola G., Alberto R., Jauregui-Haza U. J. Mol. Graph. Model., 2017, 71:167 [10]. Lamb J., Holland J.P. J. Nucl. Med., 2018, 59:382 [11]. Dijk J.D.V., Jager P.L., Osch J.A.C.V., Dalen J.A.V. J. Nucl. Med., 2017, 58:518 [12]. Nabati M., Kermanian M., Mohammadnejad-Mehrabani H., Kafshboran H.R., Mehmannavaz M., Sarshar S. Chem. Method., 2018, 3:132 [13]. Nabati M. Chem. Method., 2017, 2:128 [14]. Hernandez-Valdes D., Alberto R., Jauregui-Haza U. RSC Adv., 2016, 6:107127 [15]. Nabati M. Iran. J. Org. Chem., 2018, 10:2291 [16]. Renaud J.M., Yip K., Guimond J., Trottier M., Pibarot P., Turcotte E., Maguire C., Lalonde L., Gulenchyn K., Farncombe T., Wisenberg G., Moody J., Lee B., Port S.C., Turkington T.G., Beanlands R.S., DeKemp R.A. J. Nucl. Med., 2017, 58:103 [17]. Nabati M., Maghsoudloo-Mahalli A., Mohammadnejad-Mehrabani H., Movahed-Tazehkand H. Iran. J. Org. Chem., 2018, 10:2281 [18]. Cittanti C., Uccelli L., Pasquali M., Boschi A., Flammia C., Bagatin E., Casali M., Stabin M.G., Feggi L., Giganti M., Duatti A. J. Nucl. Med., 2008, 49:1299 [19]. Nabati M., Maghsoudloo-Mahalli A. Iran. J. Org. Chem., 2017, 9:2239 [20]. Bolzati C., Cavazza-Ceccato M., Agostini S., Refosco F., Yamamichi Y., Tokunaga S., Carta D., Salvarese N., Bernardini D., Bandoli G. Bioconjugate Chem., 2010, 21:928 [21]. Nabati M., Mohammadnejad-Mehrabani H. Iran. J. Org. Chem., 2017, 9:2117 [22]. Maria L., Soares M., Santos I.C., Sousa V.R., Mora E., Marcalo J., Luzyanin K.V. Dalton Trans., 2016, 45:3778 [23]. Nabati M., Mahkam M. Org. Chem. Res., 2016, 2:70 [24]. Nabati M. Iran. J.Org. Chem., 2016, 8:1935 [25]. Nabati M., Mahkam M. J. Phys. Theor. Chem., 2015, 12:121 [26]. Nabati M. J. Phys. Theor. Chem., 2015, 12:325 [27]. Nabati M. J. Phys. Theor. Chem., 2017, 14:49 [28]. Nabati M., Mahkam M. J. Phys. Theor. Chem., 2015, 12:33 [29]. Nabati M., Mahkam M., Atani Y.G. J. Phys. Theor. Chem., 2016, 13:35 [30]. Nabati M. J. Phys. Theor. Chem., 2016, 13:133 [31]. Moura C., Gano L., Mendes F., Raposinho P.D., Abrantes A.M., Botelho M.F., Santos I., Paulo A. Eur. J. Med. Chem., 2012, 50:350 [32]. Nabati M., Mahkam M. Inorg. Chem. Res., 2016, 1:131 [33]. Nabati M., Mahkam M. Silicon, 2016, 8:461 [34]. Nabati M. Iran. J. Org. Chem., 2015, 7:1631 [35]. Qian W., Zhang W., Zong H., Gao G., Zhou Y., Zhang C. J. Mol. Model., 2016, 22:9 [36]. Nabati M. Iran. J. Org. Chem., 2015, 7:1669 [37]. Nabati M. Iran. J. Org. Chem., 2016, 8:1703 [38]. Nabati M., Hojjati M. Iran. J. Org. Chem., 2016, 8:1777 [39]. Nabati M. Iran. J. Org. Chem., 2016, 8:1803 [40]. Nabati M. Iran. J. Org. Chem., 2016, 8:1817 [41]. Maurer R.I., Blower P.J., Dilworth J.R., Reynolds C.A., Zheng Y., Mullen G.E.D. J. Med. Chem., 2002, 45:1420 [42]. Gancheff J., Kremer C., Kremer E., Ventura O.N. J. Mol. Struct: THEOCHEM, 2002, 580:107 [43]. Okoye C.M.I. J. Phys: Condens. Matter., 2003, 15:5945 [44]. Zhang Y., Sun Y., Xu X., Zhang X., Zhu H., Huang L., Qi Y., Shen Y. J. Med. Chem., 2010, 53:3262 [45]. Banerjee P., Sproules S., Weyhermuller T., George S.D., Wieghardt K. Inorg. Chem., 2009, 48:5829 [46]. Gong Y., Zhou M., Andrews L. Chem. Rev., 2009, 109:6765 [47]. Sproules S., Benedito F.L., Bill E., Weyhermuller T., George S.D., Wieghardt K. Inorg. Chem., 2009, 48:10926
Statistics Article View: 208 PDF Download: 90